CBS DFW: EWING’S TARGETED THERAPEUTICS STORY
CBS DFW News segment on Ewing Sarcoma clinical trials at Mary Crowley Cancer Research.
EWING SARCOMA TRIAL
Mary Crowley Cancer Research has opened a new Phase I clinical trial for advanced Type 1 Ewing sarcoma, a rare bone cancer affecting children, adolescents, and young adults.
FOX 12 OREGON NEWS STORY: SAM DAY
Video News story featuring Sam Day, a patient at Mary Crowley Cancer Research and his battle with Ewing’s Sarcoma.
PUSHING HOPE: ANNUAL MARINE INDUSTRY CHARITY TOURNAMENT RAISES OVER $180,000 FOR MARY CROWLEY CANCER RESEARCH!
Pushing HOPE was the goal for The Annual Marine Industry Charity Golf, Softball and Kickball Tournaments that raised over $180,000 for Dallas’ Mary Crowley Cancer Research.
SYSTEMIC VERSUS LOCAL RESPONSES IN MELANOMA PATIENTS TREATED WITH TALIMOGENE LAHERPAREPVEC FROM A MULTI-INSTITUTIONAL PHASE II STUDY
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. The Journal for Immunotherapy of Cancer. 2016 March 15;4:12.
CUTANEOUS HEAD AND NECK MELANOMA IN OPTIM, A RANDOMIZED PHASE III TRIAL OF TALIMOGENE LAHERPAREPVEC VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF UNRESECTED STAGE
Cutaneous head and neck melanoma in OPTiM, a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
PHASE I STUDY OF CEP-37250/KHK2804, A TUMOR-SPECIFIC ANTI-GLYCOCONJUGATE MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted Oncology.
PDX1 ASSOCIATED THERAPY IN TRANSLATIONAL MEDICINE
Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. PDX1 associated therapy in translational medicine. Ann Transl Med. 2016 Jun;4(11):214
HYPOGLYCEMIA AND PDX1 TARGETED THERAPY
Hypoglycemia and PDX1 Targeted Therapy. J of Endocr Disord. 2016, 2(1): 1018-24.